MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

SectorHealthcare

2.96 0.34

Overview

Share price change

24h

Current

Min

2.92

Max

3.04

Key metrics

By Trading Economics

Income

-15M

-40M

Sales

8.2M

50M

Profit margin

-80.43

Employees

435

EBITDA

-19M

-42M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+35.59% upside

Dividends

By Dow Jones

Next Earnings

11 maj 2026

Market Stats

By TradingEconomics

Market Cap

-62M

1.1B

Previous open

2.62

Previous close

2.96

News Sentiment

By Acuity

50%

50%

170 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 kwi 2026, 23:17 UTC

Earnings

Samsung Forecasts Record First-Quarter Operating Profit

6 kwi 2026, 23:00 UTC

Hot Stocks

Stocks to Watch: Health Insurers, Mawson, Owlet

6 kwi 2026, 22:13 UTC

Major Market Movers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 kwi 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 kwi 2026, 17:09 UTC

Major Market Movers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 kwi 2026, 16:56 UTC

Major News Events

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 kwi 2026, 14:47 UTC

Major Market Movers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 kwi 2026, 00:00 UTC

Major News Events

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 kwi 2026, 23:58 UTC

Market Talk
Major News Events

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 kwi 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 kwi 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 kwi 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 kwi 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6 kwi 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 kwi 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6 kwi 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 kwi 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 kwi 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 kwi 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 kwi 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 kwi 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6 kwi 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 kwi 2026, 18:36 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 kwi 2026, 17:59 UTC

Market Talk
Major News Events

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 kwi 2026, 17:13 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 kwi 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 kwi 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 kwi 2026, 14:59 UTC

Earnings

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

35.59% upside

12 Months Forecast

Average 4 USD  35.59%

High 5 USD

Low 3 USD

Based on 6 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

170 / 349 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat